Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

4SC's Partner Yakult Honsha Starts Clinical Development with Cancer Compound Resminostat in Japan

Published: Monday, May 21, 2012
Last Updated: Monday, May 21, 2012
Bookmark and Share
The Phase I study will assess safety of resminostat in Japanese patients, which is a prerequisite of the drug's further late-stage clinical development in Japan.

4SC AG has announced that the first patient has been treated in a Japan-based Phase I clinical study with 4SC's cancer drug resminostat.

The open-arm, dose-escalating study is being conducted by Yakult Honsha, 4SC's Japanese co-development and marketing partner.

The study will evaluate safety and tolerability of resminostat in Japanese patients with advanced solid tumours. It will furthermore investigate the drug's efficacy, pharmacokinetics and pharmacodynamics.

The development of resminostat in the Japanese market is of high strategic importance to 4SC for two reasons.

In April 2011, 4SC granted an exclusive license to Yakult Honsha, the Japanese market leader in gastro-intestinal cancer therapeutics, for the development and commercialization of resminostat in Japan.

Hepatocellular carcinoma (HCC), the most common type of liver cancer with a high medical need and only few available therapeutic options has a particularly high incidence in Japan. HCC is one of the cancer indications targeted with resminostat in advanced clinical development.

Dr. Ulrich Dauer, Chief Executive Officer of 4SC AG, said: 'We are very pleased that our Japanese partner Yakult Honsha has started the clinical development of resminostat in Japan. This is of high relevance for both our alliance with Yakult in Japan and the further development strategy for resminostat in this important market. The primary goal of the study is to prove that the drug is safe and well tolerated in Japanese patients, which is a key prerequisite for resminostat's further development in this region. We are currently in discussions with regulatory authorities and potential partners to prepare for a global pivotal clinical study programme with resminostat in patients with advanced liver cancer (HCC). Given the high incidence of HCC in Japan and the whole of Asia, gaining market approval in this region is a key goal for us.'

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

4SC Discovery Collaborates with Heidelberg University Hospital
The two-year R&D project is aimed at delivering a lead compound that can be brought to clinical development with the help of potential partners.
Friday, March 21, 2014
4SC Reports Positive Data from Clinical Phase I trial with 4SC-205 in Cancer Patients
All primary objectives of the clinical study achieved.
Thursday, March 28, 2013
4SC Announces Positive Interim Results from Clinical Phase I/II SHORE Study
Phase II part of study planned to start soon in 2013.
Thursday, December 13, 2012
4SC to Present Biomarker Data for Cancer Drug Resminostat at EHA
Data from Phase II SAPHIRE trial in Hodgkin’s lymphoma presented at EHA meeting in Amsterdam.
Monday, June 18, 2012
4SC Announces Treatment of First Patient in Phase I TOPAS Study with the Selective HDAC Inhibitor 4SC-202
The study evaluate the safety, pharmacokinetics and clinical efficacy of 4SC-202 in patients with advanced hematological indications, including AML, ALL, CLL, MM, MDS and lymphomas.
Thursday, April 14, 2011
4SC Announces First Patient Dosed in Phase I/II SHORE Study with Resminostat
The first patient dosed in the study with resminostat as a second-line treatment for patients with advanced and metastatic colorectal KRAS-mutant cancer.
Friday, January 21, 2011
4SC Announces First-in-Man Phase I Results for 4SC-203
The company announces successful completion of Phase I study in healthy volunteers with the multi-target kinase inhibitor 4SC-203.
Sunday, January 09, 2011
4SC Announces Start of Dosing in First-in-Man Phase I Study with 4SC-203
This study investigates activity of 4SC-203 in 50 volunteers and comprises seven treatment cohorts.
Friday, January 22, 2010
4SC Announces Clinical Advancements in its Oncology Pipeline
The company, focused on autoimmune and cancer indications, initiates three new clinical trials for its oncology franchise.
Thursday, December 24, 2009
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Batten Disease may Benefit from Gene Therapy
NIH-funded animal study suggests one-shot approach to injecting genes.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Molecule Proves Key to Brain Repair After Stroke
Scientists found that a molecule known as growth and differentiation factor 10 (GDF10) plays a key role in repair mechanisms following stroke.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos